MMP9 and breast carcinoma: Therefore, the authors proposed that the NRF2-dependent activation of HO-1 can attenuate the metastatic potential of breast cancer cells by inhibiting the MMP-2 and MMP-9 expression and enzymatic activity but, also, cell motility through the NRF2–HO-1 axis, in agreement with the evidence from other types of tumors [36].